SCH 546738 | CAS# 906805-42-3 | CXCR3 Antagonist

MedKoo Cat#: 565367 | Name: SCH 546738

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SCH 546738 is a selective and potent CXCR3 antagonist which attenuates the development of autoimmune diseases and delays graft rejection.

Chemical Structure

SCH 546738

CAS#906805-42-3

Theoretical Analysis

MedKoo Cat#: 565367

Name: SCH 546738

CAS#: 906805-42-3

Chemical Formula: C23H31Cl2N7O

Exact Mass: 491.1967

Molecular Weight: 492.45

Elemental Analysis: C, 56.10; H, 6.35; Cl, 14.40; N, 19.91; O, 3.25

Price and Availability

Size	Price	Availability
50mg	USD 950.00	2 Weeks
100mg	USD 1,650.00	2 Weeks
1g	USD 5,950.00	2 Weeks
2g	USD 7,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SCH546738; SCH 546738; SCH-546738

IUPAC/Chemical Name

3-Amino-6-chloro-5-[(3S)-4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-3-ethylpiperazin-1-yl]pyrazine-2-carboxamide

InChi Key

UYDYJFWSPRQEAX-KRWDZBQOSA-N

InChi Code

InChI=1S/C23H31Cl2N7O/c1-2-17-14-31(23-20(25)28-19(22(27)33)21(26)29-23)11-12-32(17)18-7-9-30(10-8-18)13-15-3-5-16(24)6-4-15/h3-6,17-18H,2,7-14H2,1H3,(H2,26,29)(H2,27,33)/t17-/m0/s1

SMILES Code

O=C(C1=NC(Cl)=C(N2C[C@H](CC)N(C3CCN(CC4=CC=C(Cl)C=C4)CC3)CC2)N=C1N)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SCH 529074 restores DNA binding activity and increases DNA binding affinity of R273H and R249S with Kd values of 0.6740 and 0.4313, respectively. SCH 529074 also stimulates DNA binding activity and prevents human double minute-2 (Hdm-2) ubiquitination of wild-type p53 in vitro. SCH 529074 reduces proliferation of tumor cell lines with mutant and wild-type p53 (EC50s = 400-3,700 nM), with the p53 mutant cell lines being the most sensitive.

In vitro activity:

Low SCH 546738 concentrations (≤1 nM) efficiently inhibited CXCR3-A but not CXCR3-B's conformational change and activation. Reference: Sci Rep. 2017 Sep 6;7(1):10703. https://pubmed.ncbi.nlm.nih.gov/28878333/

In vivo activity:

In a mouse collagen-induced arthritis model, SCH 546738 attenuated disease development. SCH 546738 significantly reduced disease severity in rat and mouse experimental autoimmune encephalomyelitis model. SCH 546738 prolonged rat cardiac allograft survival in a dose-dependent manner, and when combined with Cyclosporin A it supported permanent engraftment. SCH 546738 has potential in the treatment of autoimmune diseases and prevention of transplant rejection. Reference: BMC Immunol. 2012 Jan 10;13:2. https://pubmed.ncbi.nlm.nih.gov/22233170/

	Solvent	mg/mL	mM
Solubility
	DMSO	4.5	9.14
	Water	1.0	2.03

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 492.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Boyé K, Billottet C, Pujol N, Alves ID, Bikfalvi A. Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR). Sci Rep. 2017 Sep 6;7(1):10703. doi: 10.1038/s41598-017-11151-x. PMID: 28878333; PMCID: PMC5587768. 2. Du J, Zhang X, Han J, Man K, Zhang Y, Chu ES, Nan Y, Yu J. Pro-Inflammatory CXCR3 Impairs Mitochondrial Function in Experimental Non-Alcoholic Steatohepatitis. Theranostics. 2017 Sep 26;7(17):4192-4203. doi: 10.7150/thno.21400. PMID: 29158819; PMCID: PMC5695006. 3. Jenh CH, Cox MA, Cui L, Reich EP, Sullivan L, Chen SC, Kinsley D, Qian S, Kim SH, Rosenblum S, Kozlowski J, Fine JS, Zavodny PJ, Lundell D. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 2012 Jan 10;13:2. doi: 10.1186/1471-2172-13-2. PMID: 22233170; PMCID: PMC3298469.

In vitro protocol:

In vivo protocol:

1. Du J, Zhang X, Han J, Man K, Zhang Y, Chu ES, Nan Y, Yu J. Pro-Inflammatory CXCR3 Impairs Mitochondrial Function in Experimental Non-Alcoholic Steatohepatitis. Theranostics. 2017 Sep 26;7(17):4192-4203. doi: 10.7150/thno.21400. PMID: 29158819; PMCID: PMC5695006. 2. Jenh CH, Cox MA, Cui L, Reich EP, Sullivan L, Chen SC, Kinsley D, Qian S, Kim SH, Rosenblum S, Kozlowski J, Fine JS, Zavodny PJ, Lundell D. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 2012 Jan 10;13:2. doi: 10.1186/1471-2172-13-2. PMID: 22233170; PMCID: PMC3298469.

1: Jenh CH, Cox MA, Cui L, Reich EP, Sullivan L, Chen SC, Kinsley D, Qian S, Kim SH, Rosenblum S, Kozlowski J, Fine JS, Zavodny PJ, Lundell D. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 2012 Jan 10;13:2. doi: 10.1186/1471-2172-13-2. PubMed PMID: 22233170; PubMed Central PMCID: PMC3298469.